Crossmark

Identifying individuals at extreme risk of venous thromboembolism using polygenic risk scores

Crossref DOI link: https://doi.org/10.1038/s41588-023-01330-0

Published Online: 2023-03-09

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chong, Michael http://orcid.org/0000-0002-0555-4622
Paré, Guillaume http://orcid.org/0000-0002-6795-4760
License Information

Text and Data Mining valid from 2023-03-01

Version of Record valid from 2023-03-01
More Information

Article History

First Online: 9 March 2023

Competing interests

: G.P. has received consulting fees from Illumina, Bayer and Lifelabs. M.C. has received consulting fees from Bayer and Lifelabs.